

Torrent Pharma to co-market Semaglutide injection with Zydus in India

18 March 2026 | News

Torrent will market the product under the brand name SEMBOLIC



Zydus Lifesciences and Torrent Pharmaceuticals have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market.

Under the terms of the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name SEMBOLIC™, leveraging its strong presence in chronic therapies and extensive field force across the country.

Zydus will market the product under its brand SEMAGLYN™, MASHEMA™ and ALTERME™, while Torrent Pharma will market the product under its brand SEMBOLIC™. As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus.

Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device, enabling delivery of all strengths for both indications through a single device platform.

The formulation combined with the reusable pen device is designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance, addressing key challenges in chronic disease management.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- o as monotherapy, when metformin is considered inappropriate due to intolerance or contraindications
- o in addition to other medicinal products for the treatment of diabetes

It is also indicated for use in adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.